A 72-Year-Old Woman with History of HTN, T2DM, and COPD Presents with Progressive SOB

Description

This activity is part of the Clinical Spotlight Series: What’s New in HF Pharmacotherapies: The What, How, and Wow.

Accreditation Statement

In accordance with ACCME policy, prior to participating in this activity, you must review the information on this page.

Joint Accreditation

In support of improving patient care, the American College of Cardiology Foundation (ACCF) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement
Physicians

The ACCF designates this online enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

While offering the CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Nurses
The ACCF designates this educational activity for a maximum of 0.25 continuing nursing education contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

MOC Information

Successful completion of this certified activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Target Audience:

This activity is intended for cardiovascular physicians, registered nurses, and pharmacists.   

Important Dates:
Date of Release: September 15, 2021
Term of Approval/Date of Expiration: September 14, 2022

Learner Objectives:
Upon completion of this activity, you should be able to:

Identify patient characteristics and clinical indications for SGLT2 inhibitors, including dose/dose modification, contraindications, and adverse events.

Acknowledgements:
Educational grant support provided by: AstraZeneca, Cytokinetics, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation

Faculty:

Ersilia M. DeFilippis, MD

Peer Reviewers:

Nasrien Ibrahim, MD, FACC
Alanna Morris, MD, MSc, FACC

Summary


Availability:	Retired


Cost:	FREE


Credit Offered:	No Credit Offered